Related Experiment Video

Updated: Aug 20, 2025

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.1K

Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general

M J Pérez-Granda1, P Catalán, P Muñoz

  • 1Maria Jesus Pérez, Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo, 46, 28007 Madrid, Spain. massus@hotmail.es.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|November 21, 2022
PubMed

Insights

Cytomegalovirus (CMV) reactivation was detected in 11.42% of severe COVID-19 patients, particularly those in the ICU. Early detection of CMV DNA in blood is crucial for better patient outcomes.

Area of Science:

  • Infectious Diseases
  • Virology
  • Critical Care Medicine

Background:

  • Severe COVID-19 is associated with various complications, including opportunistic infections.
  • Cytomegalovirus (CMV) reactivation is a known concern in immunocompromised individuals.

Approach:

  • A point prevalence study was conducted on 140 hospitalized patients with severe COVID-19.
  • CMV DNA in peripheral blood was determined using PCR.
  • Clinical data, including corticosteroid use and ICU admission, were analyzed.

Key Points:

  • CMV reactivation (CMV DNA presence) was observed in 11.42% of severe COVID-19 patients.
  • ICU patients showed a significantly higher prevalence (29.7%) compared to general ward patients (4.85%).
  • Higher corticosteroid doses were associated with CMV reactivation (p < 0.001).
  • CMV reactivation was often clinically unsuspected and linked to increased nosocomial infections and worse prognosis.

Conclusions:

  • Systematic screening for CMV reactivation is recommended for severe COVID-19 patients admitted to the ICU.
  • Early identification and management of CMV coinfection may improve outcomes in severe COVID-19.
Abstract

Keywords:
CMVCOVID-19coinfectioncytomegalovirusnosocomial infection

More Related Videos

qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue08:08

qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue

Published on: July 9, 2014

15.9K
A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation12:22

A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation

Published on: April 2, 2012

17.5K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Acute Pharyngitis01:30

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
1.3K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
315
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
266
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
283
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
182